Detalles de la búsqueda
1.
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial.
Int J Gynecol Cancer
; 2024 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38724236
2.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Lancet Oncol
; 23(7): 851-864, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35671774
3.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Lancet Oncol
; 21(3): 345-357, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32035020
4.
A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin.
BJU Int
; 126(2): 292-299, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32336008
5.
Fulvestrant plus capivasertib for metastatic breast cancer - Authors' reply.
Lancet Oncol
; 21(5): e234, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32359499
6.
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
Lancet Oncol
; 15(1): 114-22, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24332514
7.
Watch Me Play!: protocol for a feasibility study of a remotely delivered intervention to promote mental health resilience for children (ages 0-8) across UK early years and children's services.
Pilot Feasibility Stud
; 10(1): 55, 2024 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38576026
8.
HIDDEN2: Study protocol for the hospital deep vein thrombosis detection study in patients with cancer receiving palliative care.
BMJ Open
; 13(9): e073049, 2023 09 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37669841
9.
Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial.
EClinicalMedicine
; 52: 101595, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35990583
10.
Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial.
EClinicalMedicine
; 48: 101432, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35706488
11.
A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial.
Oncoimmunology
; 7(12): e1457597, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30524880
12.
The use of randomisation-based efficacy estimators in non-inferiority trials.
Trials
; 18(1): 117, 2017 03 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28274254
13.
Why do patients decline surgical trials? Findings from a qualitative interview study embedded in the Cancer Research UK BOLERO trial (Bladder cancer: Open versus Lapararoscopic or RObotic cystectomy).
Trials
; 17: 35, 2016 Jan 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-26787177
14.
SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma.
Eur Urol
; 67(4): 599-602, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25465968
15.
A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT).
Health Technol Assess
; 19(83): vii-xxiii, 1-93, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26490434
16.
A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective anticoagulation length with low molecular weight heparin in the treatment of cancer associated thrombosis (ALICAT): study protocol for a mixed-methods study.
Trials
; 15: 122, 2014 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24726032
17.
Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab.
Leuk Lymphoma
; 54(5): 959-66, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23020605
18.
The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus-host disease.
Transfusion
; 47(8): 1455-67, 2007 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-17655590
19.
HPA-1a antibody potency and bioactivity do not predict severity of fetomaternal alloimmune thrombocytopenia.
Transfusion
; 47(7): 1296-305, 2007 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-17581167
20.
Prevention of bedside errors in transfusion medicine (PROBE-TM) study: a cluster-randomized, matched-paired clinical areas trial of a simple intervention to reduce errors in the pretransfusion bedside check.
Transfusion
; 47(5): 771-80, 2007 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-17465940